Skip to main content
Premium Trial:

Request an Annual Quote

Motif BioSciences Closes $1.8M Financing; Funds Will Support Persian Gulf Genetics Program

NEW YORK, March 2 (GenomeWeb News) - Motif BioSciences announced today it has completed a $1.9-million financing round.

 

$500,000 of the financing was from lead investor Amphion and was announced in January. The completed financing was oversubscribed, Motif said in a statement.

 

The funding will support Motif's sample collection and analysis of two sets of genetic data from the Persian Gulf.

 

Motif BioSciences is a population genetics company using genetic data from the Persian Gulf region. It is headquartered in the US and UK and is 47-percent owned by Amphion.

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.